Lung Cancer BCOP Exam Questions with Correct Answers| Latest Update Guaranteed Success
SCLC PS 0-1 Cisplatin based regimen
SCLC PS 2-4 Lower dose Cisplatin or Carbo
SCLC brain mets WBR prior to chemo
SCLC no brain mets prophylactic cranial irradiation
When to use TKIs Mutation
Non-curative
NSCLC stage Ia/Ib No chemo
EGFR most commonly found in what subgroup Female, Asian, never smoked
NSCLC Stage IIIB (wet) All with RT
Cis/Etop 50/50
Cis/Vinblastine 100/5
Carbo/Pac 2/80
NSCLC Stage IIA, IIB, IIIA No RT
Adjuvant Cisplatin based regimen
Palliative chemo Only for PS of 0-1
, Mutation testing Only for non-squamous histology
T790M mutation (EGFR resistance mutation) Osimertinib 80 mg daily
ALK mutation 1st line Crizotinib
Ceritinib (good CNS)
Alectinib (good CNS)
ROS1 mutation 1st line Crizotinib
Ceritinib
Bevacizumab Avoid in squamous, Brain, hemoptysis
Albumin Bound Paclitaxel >70, less neuropathy, neutropenia, thrombocytopenia
Continuation therapy Bev
Pem
Gem (2B)
PD-1/PD-L1 Pembroizumab (PD-1 50% for 1st line, 1% for second line), atezolizumab,
nivolumab
Ceritinib ALK/ROS 1st line
750 mg daily
Alectinib ALK 1st line
600 mg BID
SCLC PS 0-1 Cisplatin based regimen
SCLC PS 2-4 Lower dose Cisplatin or Carbo
SCLC brain mets WBR prior to chemo
SCLC no brain mets prophylactic cranial irradiation
When to use TKIs Mutation
Non-curative
NSCLC stage Ia/Ib No chemo
EGFR most commonly found in what subgroup Female, Asian, never smoked
NSCLC Stage IIIB (wet) All with RT
Cis/Etop 50/50
Cis/Vinblastine 100/5
Carbo/Pac 2/80
NSCLC Stage IIA, IIB, IIIA No RT
Adjuvant Cisplatin based regimen
Palliative chemo Only for PS of 0-1
, Mutation testing Only for non-squamous histology
T790M mutation (EGFR resistance mutation) Osimertinib 80 mg daily
ALK mutation 1st line Crizotinib
Ceritinib (good CNS)
Alectinib (good CNS)
ROS1 mutation 1st line Crizotinib
Ceritinib
Bevacizumab Avoid in squamous, Brain, hemoptysis
Albumin Bound Paclitaxel >70, less neuropathy, neutropenia, thrombocytopenia
Continuation therapy Bev
Pem
Gem (2B)
PD-1/PD-L1 Pembroizumab (PD-1 50% for 1st line, 1% for second line), atezolizumab,
nivolumab
Ceritinib ALK/ROS 1st line
750 mg daily
Alectinib ALK 1st line
600 mg BID